Expression and putative biological roles of lipoxygenases and leukotriene receptors in leukemia and lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38992854/
This mini-review addresses lipoxygenases and receptors for leukotrienes in hematological malignancies. Potential novel biomarkers and drug targets in leukemia and B-cell lymphoma are discussed.
Targeting lipoxygenase pathways and leukotriene receptors presents a promising therapeutic strategy for hematological malignancies, offering potential novel biomarkers and drug targets in leukemia and B-cell lymphoma.
Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need
Source : https://pubmed.ncbi.nlm.nih.gov/38338868/
Recent years have seen significant improvement in chronic lymphocytic leukemia (CLL) management. Targeting B-cell lymphoma (BCL-2) and Bruton's kinase (BTK) have become the main strategies to restrain CLL activity. These...
Recent advancements in CLL management target BCL-2 and BTK. This review examines resistance mechanisms to ibrutinib and venetoclax, and explores novel treatments for double-refractory CLL.
Antineoplastic Agents
Source : https://pubmed.ncbi.nlm.nih.gov/31643354/
The antineoplastic agents or anticancer drugs represent a large and diverse class of medications. They generally have limited but important uses, and often have significant hepatotoxicity. The antineoplastic agents are...
Antineoplastic agents, diverse and classified by various methods, often cause hepatotoxicity, typically dose-related and reversible. Key agents include busulfan and melphalan.
Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia
Source : https://pubmed.ncbi.nlm.nih.gov/37389830/
T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL) is a rare hematologic malignancy most commonly affecting adolescent and young adult males. Outcomes are dismal for patients who relapse, thus, improvement...
Nelarabine effectively targets T-ALL/LBL with notable neurotoxicity. Ongoing studies explore its role in combination therapies and initial treatments to improve outcomes in relapsed and refractory cases.
Therapeutic challenges in peripheral T-cell lymphoma
Source : https://pubmed.ncbi.nlm.nih.gov/38178117/
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell leukemia and lymphoma remains less advanced,...
Understanding PTCL treatment resistance involves exploring tumor heterogeneity, the microenvironment, and signaling pathways. Ongoing trials aim to improve outcomes for patients with relapsed or refractory PTCL.